News and Announcements
SUDA granted meeting with UK MHRA for approval of ZolpiMist™
- Published May 25, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted SUDA a meeting on 21 June 2017 to discuss the proposed plan for registration of SUDA’s novel ZolpiMist™ oral spray of zolpidem tartrate to treat insomnia in the UK and European Union.
KEY TAKEAWAYS:
- SUDA is seeking advice on the suitability of its regulatory strategy which is to file for approval of ZolpiMist in Europe based on the data that successfully resulted in the product’s US FDA approval.
- The proposed regulatory dossier is intended to support a marketing authorisation application to either the MHRA or the European Medicines Agency.
- SUDA will be seeking advice from the MHRA on the acceptability of the excipients used in the ZolpiMist oral spray formulation which are all listed in the US pharmacopeia.
Mr Stephen Carter, SUDA’s CEO and Managing Director, commented: “It is estimated that about 100 million people suffer from some sort of insomnia in the EU (source: EFPIA). There remains a significant unmet need for new treatment options, particularly for patients that want rapid onset of sleep, have problems swallowing tablets or have gastrointestinal complications. For these patients, ZolpiMist offers an attractive alternative with rapid absorption of the drug through the oral mucosa. We look forward to the feedback from the MHRA and to bringing ZolpiMist to market in this key territory.”
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
